RESUMEN
Objective:To retrospectivey analyze of serum alkaline phosphatase (ALP), calcium levels in lung cancer patients undergoing bone scan (ECT) in order to evaluate their clinical values in diagnosis of bone metastases. Methods:The results of blood ALP, calcium (Ca2+) and ECT findings from 81 cases of lung cancer patients with bone metastases and 43 cases without bone metastases were collected,the levels of ALP,calcium were compared between the two groups. Lung cancer patients were performed a grading classification for the bone metastasis,serum ALP,calcium levels were analysed. The clinical values of serum ALP,calcium in monitoring bone metastasis were evaluated through receiver operating characteristic (ROC) curve. Results:(1) The serum levels of ALP,calcium in lung cancer patients with bone metastases were higher than those in patients without bone metastases (P<0.01) . (2) Grade Ⅲ patients had a significantly higher blood ALP level than grade Ⅰ, grade Ⅱ patients (P=0.003), whereas serum calcium levels were higher in gradeⅠpatients than that in gradeⅡ,Ⅲpatients,but there was no significant difference (P>0.05) . (3) The area under the curve (AUC) of blood ALP, calcium in lung cancer patients were 0.715, 0.769, respectively, when detection was combined, the sensitivity increased to 70.4%, and specificity remained at a high level. Conclusion:ECT combined with blood ALP, calcium has a diagnostic value in the detection of bone metastases in lung cancer patients, and can be used as a screening and monitoring methods.
RESUMEN
Objective To assess the effect of Lep d2 from Lepidoglyphus destructor as a vaccine for specific immunothera?py on murine model of asthma. Methods Thirty BALB/c mice(SPF)were randomly categorized into a PBS group,an asthma group,and a Lep d2 SIT group. The mice in the asthma group and Lep d2 SIT group were sensitized by intraperitoneal injection with extracts of dust mites on Days 0,7th,and 14th,while those in the PBS group were injected with PBS. From the 21st day, the asthma group and Lep d2 SIT group exposed to the extracts of dust mites were stimulated by aerosol inhalation for 7 succes?sive days. During the period of the 25th-27th Day,the mice in Lep d2 SIT group were injected intraperitoneally with Lep d2 al?lergen for SIT 30 min before nasal inhalation,whereas the PBS group and asthma group were treated with only PBS. Twenty?four hours after the final inhalation,all the mice were sacrificed,the bronchoalveolar lavage fluids(BALFs)were collected. The lev?els of IFN?γ,IL?5 and IL?13 in the BALF and the supernatant of splenocyte culture solution(SSCS)as well as the levels of spe?cific IgE(sIgE)and sIgG2a in the sera were detected by ELISA. The lung tissues of the mice in the above 3 groups were stained by haematoxylin and eosin(H&E)and observed by a microscope. Results The symptoms of acute asthma attack were observed in the mice of the asthma group and Lep d2 group,but not in the PBS group. The allergic inflammation changes in lung in the Lep d2 SIT group were significantly alleviated compared with those in the asthma group. The concentrations of IFN?γin BALFs and SSCS of the mice in the Lep d2 SIT group were significantly higher than those in the asthma group(both P<0.01),while the levels of IL?5 and IL?13 in the former group were significantly lower than those in the latter group(all P<0.01). Mean?while,the level of sIgE of mice in the Lep d2 SIT group was significantly lower than those in the asthma group(P<0.01),while the level of sIgG2a of mice in the former group was higher than those in the latter group(P<0.01). Conclusion Lep d2 allergen as a vaccine can alleviate the allergic symptoms in the lung of mice effectively after allergen specific immunotherapy.
RESUMEN
Objective To investigate the influence of simvastatin on inflammatory indices in nasal lavage,sputum and blood and clinical index in patients with chronic obstructive pulmonary diseases (COPD). Methods Thirty-seven stable COPD patients were randomly divided into simvastatin-treatment group (n=17),orally given simvastatin tablets for 4 weeks in addition to basic therapy,40 mg,qd) and control group (n=20),given usual med-ication). Total cell counts,percentage of leukocytes (N%) and levels of interleukin IL-8,IL-6 in nasal lavage and sputum at pre-post-treatment were compared;Serum C-reactive protein (CRP),total cholesterol (TC),low-density lipoprotein-cholesterol (LDL-C) as well as IL-8,IL-6 concentrations were measured,the variation of lung function,Sino-Nasal Outcome Test 20(SNOT-20) and St George's Respiratory Questionnaire(SGRQ) score were analyzed. Results After the treatment,the nasal lavage and sputum total cell counts,N%,IL-8 and IL-6 levels[nasal lavage: (0.7±0.3)×107/L,(41.1±10.9)%,(105.8±74.5) ng/L,(3.8±1.6) ng/L;sputum: (0.8±0.3)×109/L,(56.6±9.6) %,(2565.5±831.9) ng/L,(109.8±42.3) ng/L] dropped slightly in the simvastatin group com-pared with that at pretreatment [nasal lavage: (0.8±0.3)×107/L,(43.2±10.8) %,(107.6±86.3) ng/L,(4.1±1.9)ng/L;sputum: (0.8±0.3)×109/L,(58.1±9.3)% ,(2659.4±885.2) ng/L,(111.8±46.6) ng/L] (P>0.05) ;There were significant decreases in serum CRP [(4.3±3.7) mg/L vs (2.6±1.8) mg/L],IL-6 [(4.8±2.0)ng/L vs(4.7±1.9)ng/L] ,TC[(4.2±1.0) mmol/L vs(3.7±0.8)mmol/L] ,LDL-C[(2.4±0.5) mmol/L vs (2.2±0.5)mmol/L] (P>0.05) ;IL-8 concentrations in serum were lower gently[(6.2±1.8) ng/L vs (6.4±1.9) ng/L] (P>0.05). Significant change of simvastatin treatment on SGRQ was only reflected in the symp-tom score [pre-post-treatment:39.6±10. 8 vs 32.3±11.6,P<0.05,respectively],while other observation items (SNOT-20,FEV1%,FEV1/FVC) changed not notably (P>0.05). No marked changes in inflammatory markers and quality of life scores,lung function were observed in control group (P>0.05). Conclusion Simvastatin may be as-sociated with the potential to alleviate systemic inflammation and relieve symptoms in COPD patients.